RxDoctor Payments Data

Kelsey Simmons, DO

Family Medicine · Hope Mills, NCNPI 1831545383

Payments from drug & device makers

$2,546in general payments, 2019–2025

Across 79 payments — averaging $32.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Lilly USA, LLC$212
  • Johnson & Johnson$188
  • UCB, Inc.$149
  • AbbVie$112
  • Amgen$102
  • plus $354 from 9 others

What the payments were for

  • Travel & lodging$1,11744%
  • Food & beverage$1,42956%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,546 in reported general payments places this provider in the 80th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$86,345
Medicare patients
209
Services billed
1,212

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide63$90,028
JardianceEmpagliflozin52$75,184
JanuviaSitagliptin Phosphate45$55,492
RybelsusSemaglutide28$49,703
TrulicityDulaglutide34$49,029
EliquisApixaban46$48,843
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$39,440
MounjaroTirzepatide25$28,298
LinzessLinaclotide36$26,605
Tresiba Flextouch U-100Insulin Degludec12$17,099
FarxigaDapagliflozin Propanediol12$16,541
MyrbetriqMirabegron24$14,126
Advair HfaFluticasone Propion/Salmeterol34$11,071
Incruse ElliptaUmeclidinium Bromide14$10,582
XareltoRivaroxaban18$9,834

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$86$139,73091 claims
Lilly USA, LLCTrulicity, Mounjaro$212$77,32759 claims
Boehringer IngelheimJardiance$15$75,18452 claims
AbbVieLinzess, Synthroid$112$28,32958 claims
AstraZenecaFarxiga$29$16,54112 claims
Johnson & JohnsonXarelto$188$9,83418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Hope Mills

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →